The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Current understanding and management of CAR T cell-associated toxicities
Open accessAbstract
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several haematological malignancies and is being investigated in patients with various solid tumours. Characteristic CAR T cell-associated toxicities such as cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are now well-recognized, and improved supportive care and management with immunosuppressive agents has made CAR T cell therapy safer and more feasible than it was when the first regulatory approvals of such treatments were granted in 2017. The increasing clinical experience with these therapies has also improved recognition of previously less well-defined toxicities, including movement disorders, immune effector cell-associated haematotoxicity (ICAHT) and immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), as well as the substantial risk of infection in patients with persistent CAR T cell-induced B cell aplasia and hypogammaglobulinaemia. A more diverse selection of immunosuppressive and supportive-care pharmacotherapies is now being utilized for toxicity management, yet no universal algorithm for their application exists. As CAR T cell products targeting new antigens are developed, additional toxicities involving damage to non-malignant tissues expressing the target antigen are a potential hurdle. Continued prospective evaluation of toxicity management strategies and the design of less-toxic CAR T cell products are both crucial for ongoing success in this field. In this Review, we discuss the evolving understanding and clinical management of CAR T cell-associated toxicities. Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of various haematological malignancies but is associated with characteristic toxicities as well as less well-defined adverse effects, many of which can be severe and potentially fatal. The increasing clinical experience with CAR T cell products has resulted in better recognition and management of these toxicities using a range of pharmacotherapies, although this is an area of continued evolution and refinement. In this Review, Brudno and Kochenderfer discuss the current understanding and clinical management of CAR T cell-associated toxicities. As clinicians have gained more experience with chimeric antigen receptor (CAR) T cell therapy, the management of cytokine-release syndrome (CRS) has improved, especially with use of the IL-6 receptor antagonist tocilizumab. In addition, monitoring and treatment of immune effector cell-associated neurotoxicity syndrome (ICANS) has improved with refinements to supportive care and glucocorticoid use. Movement disorders are an infrequent complication of B cell maturation antigen (BCMA)-directed CAR T cells, are difficult to manage and can be life-threatening. Prolonged cytopenias, secondary haemophagocytic lymphohistiocytosis and infectious complications are increasingly well recognized, and consensus guidelines have been developed for their management. New T cell malignancies have been reported after CAR T cell therapy but are exceedingly rare. Patients should be monitored for second malignancies indefinitely following CAR T cell therapy. Future directions in this field include the development of less-toxic CAR T cell products. As clinicians have gained more experience with chimeric antigen receptor (CAR) T cell therapy, the management of cytokine-release syndrome (CRS) has improved, especially with use of the IL-6 receptor antagonist tocilizumab. In addition, monitoring and treatment of immune effector cell-associated neurotoxicity syndrome (ICANS) has improved with refinements to supportive care and glucocorticoid use. Movement disorders are an infrequent complication of B cell maturation antigen (BCMA)-directed CAR T cells, are difficult to manage and can be life-threatening. Prolonged cytopenias, secondary haemophagocytic lymphohistiocytosis and infectious complications are increasingly well recognized, and consensus guidelines have been developed for their management. New T cell malignancies have been reported after CAR T cell therapy but are exceedingly rare. Patients should be monitored for second malignancies indefinitely following CAR T cell therapy. Future directions in this field include the development of less-toxic CAR T cell products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 4×
“Retrospective analyses of data from clinical trials indicate that the use of tocilizumab to treat established CRS has no effect on blood CAR T cell levels 8,40 .”
InfluentialTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112 · cited 1×
“75) was used to grade neurological toxicity in the first trials leading to FDA approval of all now commercially available CAR T cell products 1,2,4,5,8–10 except cilta-cel, for which neurological toxicity was graded using the ASTCT ICANS scale in the phase II portion of the CARTITUDE-1 trial 11 .”
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 7×
“In the initial pivotal trials of the currently approved CAR T cell therapies, use of anakinra for the management of active ICANS was limited to a few patients 10,11 , although this agent is now commonly used as the standard-of-care treatment for glucocorticoid-refractory ICANS 58,62 .”
InfluentialEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Cited by
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 359
Self-citationCao, L.-Y., Zhao, Y., Chen, Y., Ma, P., Xie, J.-C., Pan, X.-M., Zhang, X., Chen, Y.-C., Wang, Q., & Xie, L.-L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583116 · Cited by 53
Metadata
- Authors
- Brudno, J. N., & Kochenderfer, J. N.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2024-05-20
- Volume
- 21
- Issue
- 7
- Pages
- 501-521
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W4398142342
- Cited by
- 305
- References
- 168
- FWCI
- 24.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current understanding and management of CAR T cell-associated toxicities. https://app.cochat.ai/papers/10.1038/s41571-024-00903-0
- The paper
- Brudno, J. N., & Kochenderfer, J. N. (2024). Current understanding and management of CAR T cell-associated toxicities. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-024-00903-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.